Healthcare wanted a turn at the mic today and got it. Liquidia’s unaudited 2025 scorecard hit after-hours with real revenue and real cash, not the usual biotech PowerPoint. That pulled attention into pulmonary hypertension and inhaled therapies, while liquidity magnets in big pharma kept the sector bid as we head into J.P. Morgan week.
Technology still hogged the tape, but healthcare elbowed in thanks to a rare combo: a small-cap biotech printing sales and cash flow, and a sector catalyst runway that stretches through January conferences. Liquidia’s YUTREPIA update was the spark. In a market crowding into AI, anything that expands the definition of growth outside semis gets instant attention, and inhaled treprostinil just crashed the party.
What drove attention today: The company released preliminary, unaudited full-year 2025 numbers for YUTREPIA, its inhaled treprostinil. Net product sales landed around 148.3 million for 2025, including 90.1 million in the fourth quarter alone, more than 2,800 unique patient prescriptions since the June launch, and over 30 million in positive cash flow in Q4. Cash stood at roughly 190.7 million heading into 2026. Management will roadshow the story at the J.P. Morgan Healthcare Conference next week with an aggressive clinical expansion plan across PAH, PH-ILD, IPF, PPF, and PH-COPD. Trading profile: Small-cap biotech with event-driven flows, a fresh commercial ramp, and a high-beta tape presence. Options-friendly, short-squeeze adjacent, and sensitive to competitor headlines. Key takeaway: YUTREPIA’s early traction de-risks the commercial arc and reframes Liquidia from “science project” to “emerging revenue platform.” The 2026 pipeline studies and L606 read-through extend the narrative beyond the initial launch. It is now about execution against a larger inhaled prostacyclin market, not proving the drug works.
What drove attention today: Read-through. Liquidia’s update forces a look at the broader prostacyclin ecosystem dominated by United’s Tyvaso and Tyvaso DPI. If the category is expanding, that’s a tailwind for UTHR’s franchise. If share shifts accelerate, that’s the risk. Investors also assess whether pricing and access hold in a more competitive inhaled market. Trading profile: Profitable, cash-rich biotech with a pulmonary hypertension cash machine and a pipeline designed to feed durable growth. Lower beta than the average biotech, but not immune to competitive shocks. Key takeaway: Category growth vs. share loss is the central debate. Liquidia’s numbers suggest inhaled treprostinil demand is robust, which can be a rising-tide outcome for United if it holds its base and leans on device convenience and payer relationships. Watch for JPM commentary on Tyvaso DPI momentum and any guardrails around pricing.
What drove attention today: Sympathetic move on the inhaled therapy theme. MannKind provides the platform behind Tyvaso DPI, so any change in United’s volumes or competitive dynamics matters for MNKD’s royalty streams. Liquidia’s adoption underscores patient and prescriber comfort with inhaled delivery in pulmonary hypertension, which keeps MannKind in the conversation. Trading profile: Small-cap healthcare hardware and royalty story with idiosyncratic catalysts. Liquidity comes in waves around partner updates and sector rotations. Volatility premium is standard. Key takeaway: Exposure to the Tyvaso DPI engine is both the gift and the risk. A bigger inhaled prostacyclin market is constructive, but incremental competition from YUTREPIA will keep a cap on multiple expansion until visibility on United volumes improves. Royalty math wins if category growth outruns share shifts.
What drove attention today: Healthcare leadership flows favored the GLP-1 bellwether again. With tech dictating index beta, capital still wants a second pillar of growth, and Lilly’s obesity and diabetes portfolio supplies it. As JPM week approaches, investors position around capacity updates, label expansions, and long-duration growth guidance. Trading profile: Mega-cap pharma turned growth compounder. Heavily owned by generalists and quants alike, lower beta than biotech one-trick ponies, but still a momentum barometer for the entire healthcare complex. Key takeaway: Lilly sets the valuation ceiling for premium growth in healthcare. The stock’s multiple is a referendum on whether investors will pay tech-like prices for durable drug growth. For the rest of the sector, Lilly’s strength provides cover and risk: cover because it attracts flows into healthcare, risk because it hogs them when fundamentals elsewhere disappoint.
What drove attention today: Respiratory season, JPM positioning, and pipeline curiosity kept it on screens. Investors weigh near-term revenue from COVID and other respiratory programs against mid-stage pipeline readouts and combo vaccine ambitions. In a market starving for non-AI volatility, Moderna offers it with a cash buffer that lets management keep swinging. Trading profile: High-beta, catalyst-driven, and sentiment-sensitive. Cash-rich from the pandemic era, but the path to steady-state revenue is debated every quarter. Options activity is standard fare around conferences and data cadence. Key takeaway: If healthcare is going to trade like growth again, Moderna remains one of the sector’s cleaner expressions of optionality. Successive proof points on RSV, flu, and CMV can compress the discount rate investors apply to post-COVID revenue. Misses and delays bring the usual penalty box. Position sizing does the risk management for you.
Healthcare just reminded the market it can print growth away from the GLP-1 mania. Liquidia showed that execution can flip a biotech from speculative to cash generative in two quarters. That changes how investors handicap small and mid-cap pipelines heading into JPM, where the rumor mill and meeting rooms decide who gets oxygen for the next six months. The prostacyclin lane looks bigger, not smaller. The harder question is how that bigger pie gets sliced between incumbents, new entrants, and device partners.
Today’s tape said two things. First, real numbers beat slide decks. Liquidia earned attention by delivering sales, prescriptions, and cash flow ahead of the biggest healthcare conference of the year. Second, sector leadership remains barbelled: mega-cap compounding from Lilly on one end, high-beta optionality from names like Moderna on the other, with strategic read-throughs for United Therapeutics and MannKind in the middle.
For investors, lean into catalysts with revenue credibility and clean read-throughs. Inhaled prostacyclins are now a battleground with expanding demand and multiple publicly traded ways to play it. Let the conference chatter set the near-term winners, but keep your eyes on execution, access, and cash conversion—because even in biotech, cash flow still talks.
